Screener
SELLAS Life Sciences Group, Inc. SLS Total Revenue
Discontinued — last reported Q4 '23
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: SELLAS Life Sciences Group, Inc.’s 10-K, filed March 28, 2024.
- Filed
- Mar 28, 2024
- Fiscal year
- FY2023
- Accession
- 0001390478-24-000004
| Line item | Year Ended December 31, 2023 | 2022 |
|---|---|---|
| Licensing revenue | — | $1,000 |
| Operating expenses: | ||
| Cost of licensing revenue | — | 100 |
| Research and development | 24,007 | 20,268 |
| General and administrative | 13,862 | 12,582 |
| Acquired in-process research and development | — | 10,000 |
| Total operating expenses | 37,869 | 42,950 |
| Loss from operations | (37,869) | (41,950) |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is SELLAS Life Sciences Group, Inc.'s total revenue?
- SELLAS Life Sciences Group, Inc. (SLS) reported total revenue of $0 in Q4 2023.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s total revenue?
- Over 2 years (2021 to 2023), SELLAS Life Sciences Group, Inc.'s total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $7.6M to $0.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about SELLAS Life Sciences Group, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude